The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor

被引：14

作者：

Zhang, Qiangsheng ^{[1
]}

Hu, Xi ^{[1
]}

Li, Lu ^{[2
]}

Zhang, Lidan ^{[1
]}

Wan, Guoquan ^{[1
]}

Feng, Qiang ^{[3
]}

Zhu, Yongxia ^{[4
]}

Wang, Ningyu ^{[5
]}

Liu, Zhihao ^{[1
]}

Yu, Luoting ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, West China Med Sch,Collaborat Innovat Ctr Biother, Chengdu 610041, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Inst Clin Trials, Chengdu 610041, Sichuan, Peoples R China

[3] Chengdu Normal Univ, Coll Chem & Life Sci, Chengdu 611130, Peoples R China

[4] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Clin Pharm, Chengdu 610041, Peoples R China

[5] Southwest JiaoTong Univ, Sch Life Sci & Engn, Chengdu 611756, Sichuan, Peoples R China

来源：

CHEMICAL COMMUNICATIONS | 2021年 / 57卷 / 24期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1039/d0cc04670a

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

By targeting the unique Cys663 of EZH2, SKLB-0335 displays high paralog-selectivity on EZH2. Biochemical studies show that SKLB-0335 can covalently bind to EZH2 at its S-adenosylmethionine (SAM) pocket and inhibit H3K27Me3. SKLB-0335 could be an effective chemical probe with which to further investigate the specific biological functions of EZH2.

引用

页码：3006 / 3009

页数：4

共 50 条

[1] Anti-tumor activity of SKLB-0322, a novel EZH2 covalent inhibitor, in ovarian cancer.
Zhu, Yongxia
Chen, Xinyi
Zhang, Qiangsheng
Shi, Lihong
Yu, Luoting
Xiao, Hongtao
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Discovery of dihydropyridinone derivative as a covalent EZH2 degrader
Zhou, Bin
Wang, Beilei
Zou, Fengming
Mei, Husheng
Liu, Qingwang
Qi, Shuang
Wang, Wenliang
Jin, Rui
Wang, Aoli
Chen, Yongfei
Liu, Feiyang
Wang, Wenchao
Liu, Jing
Liu, Qingsong
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 261
[3] SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer
Zhu, Y.
Chen, X.
Zhang, Q.
Zeng, J.
Xiao, H.
Yu, L.
ANNALS OF ONCOLOGY, 2022, 33 : S7 - S7
[4] Paralog-selective ligands for Bcl-2 proteins
Gemperli, AC
Rutledge, SE
Maranda, A
Schepartz, A
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (06) : 1596 - 1597
[5] Convergent Synthesis and Discovery of a Natural Product-Inspired Paralog-Selective Hsp90 Inhibitor
Jeso, Valer
Cherry, Lisa
Macklin, Todd K.
Pan, Subhas Chandra
LoGrasso, Philip V.
Micalizio, Glenn C.
ORGANIC LETTERS, 2011, 13 (19) : 5108 - 5111
[6] Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer
Zhang, Qiangsheng
Chen, Xinyi
Cao, Jiaying
Yang, Wan
Wan, Guoquan
Feng, Qiang
Zhou, Shuyan
Yang, Hongling
Wang, Ningyu
Liu, Zhihao
Xiao, Hongtao
Zhu, Yongxia
Yu, Luoting
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (03) : 1725 - 1741
[7] Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer
Zhang, Qiangsheng
Chen, Xinyi
Cao, Jiaying
Yang, Wan
Wan, Guoquan
Feng, Qiang
Zhou, Shuyan
Yang, Hongling
Wang, Ningyu
Liu, Zhihao
Xiao, Hongtao
Zhu, Yongxia
Yu, Luoting
JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 1725 - 1741
[8] Paralog-selective ligands for Bcl-2 proteins
Gemperli, Anja C.
Rutledge, Stacey E.
Maranda, Abby
Schepartz, Alanna
Journal of the American Chemical Society, 2005, 127 (06): : 1596 - 1597
[9] A PARALOG-SELECTIVE INHIBITOR MAY ALLOW FOR TARGETING OF GSK3α IN AML
不详
CANCER DISCOVERY, 2018, 8 (05) : 528 - 528
[10] Discovery of a first-in-class EZH2 selective degrader
Anqi Ma
Elias Stratikopoulos
Kwang-Su Park
Jieli Wei
Tiphaine C. Martin
Xiaobao Yang
Megan Schwarz
Violetta Leshchenko
Alexander Rialdi
Brandon Dale
Alessandro Lagana
Ernesto Guccione
Samir Parekh
Ramon Parsons
Jian Jin
Nature Chemical Biology, 2020, 16 : 214 - 222

← 1 2 3 4 5 →